| http://www.w3.org/ns/prov#value | - The BARDA Contract also separately contains $178.4 million of options that, if exercised by BARDA: would fund development and supportive activities such as work on pediatric and geriatric formulations of the drug as well as use of Tecovirimat 3Table of Contentsfor smallpox prophylaxis; would result in a $50 million payment to the Company for FDA approval for extension to 84-month expiry for Tecovi
|
